Rezolute Inc Stock

$5.94

2.24% yesterday

Nasdaq, Aug 11, 10:00 pm CET

ISIN

US76200L3096

Symbol

RZLT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Rezolute Inc Stock price

$5.94

-13.06 68.74% 5Y

Nasdaq, Closing price Mon, Aug 11 2025

+0.13 2.24%

ISIN

US76200L3096

Symbol

RZLT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$516.8m

Enterprise Value

$429.9m

Net debt

positive

Cash

$86.9m

Shares outstanding

60.5m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

6.3

Financial Health

Equity Ratio

91.2%

Return on Equity

-56.2%

ROCE

-91.5%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-77.0m | -

EBIT

$-77.0m | $-77.2m

Net Income

$-73.0m | $-57.0m

Free Cash Flow

$-65.1m

EPS

$-1.0

FCF per Share

$-1.1

Short interest

11.7%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Get Started for Free Today

Rezolute Inc Stock Analysis

Unlock Scores for Free

??

16 Analysts have issued a Rezolute Inc forecast:

15x Buy

94%

More details on Analyst Estimates Including Price Targets

16 Analysts have issued a Rezolute Inc forecast:

Buy

94%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Rezolute Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	17 17	24% 24% -
- Research and Development Expense	60 60	26% 26% -
EBITDA	-77 -77	26% 26% -
- Depreciation and Amortization	0.03 0.03	25% 25% -
EBIT (Operating Income) EBIT	-77 -77	26% 26% -
Net Profit	-73 -73	26% 26% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Rezolute Inc Stock News

Neutral

GlobeNewsWire

●

21 days ago

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 29-30, 2025.

Neutral

GlobeNewsWire

●

about one month ago

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

REDWOOD CITY, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today announced that the abstract titled “Preliminary Patient Demographics And Baseline Characteristics From A Phase 3 Study (sunRIZE) Of Ersodetug For Hypoglycemia Due To Congenita...

Neutral

GlobeNewsWire

●

3 months ago

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

Target enrollment exceeded with 62 participants enrolled, including approximately 15 percent from U.S. sites Topline data is anticipated in December of 2025 REDWOOD CITY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today announced that enro...

More Rezolute Inc News

Company Profile

Rezolute, Inc. is biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products portfolio include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperInsulinism; AB101-Phase 1, a once-weekly injectable basal insulin; and RZ402 which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.

Head office	United States
CEO	Nevan Elam
Employees	55
Founded	2010
Website	www.rezolutebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now